Revenue - Products Sales was TFA Therapeutics’s largest product and service line in fiscal 2025, bringing in $1.07M of $1.25M (86%).
| Product and Service | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue - Products Sales | $601.57K | $1.20M | $1.07M | ||
| Sales Of Cordyceps | — | — | — | ||
| Revenue - Training | $154.11K | — | — | ||
| Revenue - Related Parties | $126.86K | $52.94K | $175.41K | ||
| Training Of Cordyceps Cultivation | — | — | — | ||
| Total | $882.53K | $1.25M | $1.25M |
TFA Therapeutics brought in $1.25M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 0.6% from $1.25M in fiscal 2024. Revenue - Products Sales was the largest at $1.07M (85.9%), ahead of Revenue - Related Parties at $175.41K (14.1%).
Compared with fiscal 2024, Revenue - Related Parties grew 231.3% to $175.41K, while Revenue - Products Sales fell 10.9% to $1.07M.
TFA Therapeutics stopped reporting Revenue - Training as a separate line after fiscal 2023, when it brought in $154.11K.
TFA Therapeutics (RAJAF) reports its revenue by product and service. In fiscal 2025, Revenue - Products Sales was its largest product and service line, bringing in $1.07M (85.9% of the total), followed by Revenue - Related Parties at $175.41K (14.1%).
Revenue - Products Sales was TFA Therapeutics' largest product and service line in fiscal 2025, bringing in $1.07M, or 85.9% of the $1.25M total across its two product and service lines.
Revenue - Related Parties grew faster than Revenue - Products Sales in fiscal 2025, up 231.3% from $52.94K to $175.41K. Revenue - Products Sales fell 10.9% to $1.07M.
Every figure comes from TFA Therapeutics' annual financial filings, as reported. Each line keeps the name TFA Therapeutics gives it, and years follow its fiscal calendar.
TFA Therapeutics' revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.